Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times ...

The state Department of Health is partnering with Diagnostic Laboratory Services and Clinical Laboratories of Ha-wai’i to encourage providers to do “reflex” hepatitis C testing, in hopes of screening ...

Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists. This is an ASCO Meeting Abstract from the ...

Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in Muenster, Germany. Ridom´s NGS ...

Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored This study of mutation testing in patients with NSCLC 25 and other studies that are measuring other genetic ...